| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 11,002 | 13,026 | ||
| Accounts receivable | 448 | - | ||
| Inventory | 1,149 | 948 | ||
| Income taxes receivable | 0 | 0 | ||
| Prepaid expenses and other current assets | 1,128 | 916 | ||
| Total current assets | 13,727 | 14,890 | ||
| Intangible asset, net | 18,710 | 19,059 | ||
| Property and equipment, net | 18 | 12 | ||
| Restricted cash | 29 | 34 | ||
| Other assets | 19 | 19 | ||
| Total assets | 32,503 | 34,014 | ||
| Accounts payable | 577 | 1,189 | ||
| Accrued expenses | 5,216 | 3,951 | ||
| Exchangeable notes | 0 | 0 | ||
| Royalty-linked notes | 281 | 190 | ||
| Income taxes payable | 24 | 6 | ||
| Other current liabilities | 332 | 197 | ||
| Total current liabilities | 6,430 | 5,533 | ||
| Pfizer promissory note | 21,215 | 20,653 | ||
| Royalty-linked notes | 12,239 | 11,715 | ||
| Total liabilities | 39,884 | 37,901 | ||
| Ordinary shares, 0.01 par value per share 80,000,000 shares authorized at september 30, 2025 and december 31, 2024, 48,991,860 shares issued at september 30, 2025 31,534,233 shares issued at december 31, 2024 | 490 | 421 | ||
| Additional paid in capital | 498,580 | 493,164 | ||
| Accumulated other comprehensive income | - | 0 | ||
| Accumulated deficit | -506,451 | -497,472 | ||
| Total shareholders' deficit | -7,381 | -3,887 | ||
| Total liabilities and shareholders' deficit | 32,503 | 34,014 | ||
Iterum Therapeutics plc (ITRM)
Iterum Therapeutics plc (ITRM)